TNYA · Tenaya Therapeutics, Inc.
$0.70
+0.01 (+0.98%)
At close · Aug 21
Market Cap
$156.36M
Shares
224.23M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$90.6M
+18.5%
FY2025
Diluted EPS
-$0.59
+55%
FY2025
Operating Cash Flow
-$68.26M
+24.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $61.61M | $68.61M | $86.74M | $98.04M | $94.54M | $54.39M | $31.1M | |
| $22.4M | $24.72M | $29.21M | $33.16M | $31.08M | $18.41M | $7.81M | |
| $7.14M | $8.44M | $8.47M | $8.69M | $6.47M | $2.96M | $2.48M | |
| $107.2M | $93.33M | $115.95M | $131.19M | $125.62M | $72.81M | $38.91M | |
| -$105.86M | -$93.33M | -$115.95M | -$131.19M | -$125.62M | -$72.81M | -$38.91M | |
| $2.72M | $2.68M | $4.74M | $7.06M | $1.95M | $108K | $87K | |
| $2.75M | $2.73M | $4.82M | $7.11M | $1.96M | $85K | $517K | |
| -$103.12M | -$90.6M | -$111.13M | -$124.08M | -$123.67M | -$72.72M | -$38.4M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$103.12M | -$90.6M | -$111.13M | -$124.08M | -$123.67M | -$72.72M | -$38.4M | |
| -$103.11M | -$90.63M | -$111M | -$123.81M | -$123.9M | -$72.86M | -$38.4M | |
| USD/shares | — | -$0.59 | -$1.31 | -$1.68 | -$2.76 | -$4.10 | — |
| USD/shares | — | -$0.59 | -$1.31 | -$1.68 | -$2.76 | -$4.10 | — |
| shares | — | 152.97M | 84.82M | 73.79M | 44.82M | 17.73M | 972.09K |
| shares | — | 152.97M | 84.82M | 73.79M | 44.82M | 17.73M | 972.09K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2021: $14K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.12×
EV/EBIT
—
Peer median 10.95×
P/E (TTM)
—
Peer median 9.32×
Peer medians compare against the 307 similar-size Biotechnology companies (of 546 listed).
Key facts
CIK
1858848
CUSIP
87990A106
13F (30d)
85 filings
85 filers
Visit website
Investor relations